LivaNova PLC (LIVN) Stock AnalysisLIVNLivaNova PLC

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

LivaNova PLC (LIVN) is a good buy right now due to its strong financial performance and positive analyst sentiment. The current price is $80.90, with a forward P/E of 16, indicating attractive valuation relative to future earnings. Additionally, the stock has experienced a 49.04% increase over the past year, outperforming the S&P 500's 16.2% return, which reflects strong market confidence. The main risk is the recent insider activity where a director sold 1,650 shares, reducing his stake by 17%, which could raise concerns about insider sentiment.

9 analysts cover LIVN: 5 rate it Buy, 3 Hold and 1 Sell. The average price target is 72.50.